Advanced therapy medicinal products: a comprehensive overview for pharmacy professionals An overview of the clinical, institutional, regulatory, safety and economic considerations of advanced therapy medicinal products.…
We must learn the lessons from Priadel The discontinuation of Priadel shows we need a tougher regulatory environment to prevent firms making commercial decisions that put vulnerable patients at risk.…
UK could see ‘influx of counterfeit medicines’ without FMD after Brexit, warns RPS The UK could see “an influx of counterfeit medicines” after the Falsified Medicines Directive ceases to apply at the end of the Brexit transition period on 1 January 2021, the Royal Pharmaceutical Society has warned.…
Competition watchdog launches investigation into discontinuation of bipolar drug The Competition and Markets Authority has launched an investigation into Essential Pharma’s decision to discontinue the first-line treatment for bipolar disorder, Priadel.…
NHS England boss accuses Priadel manufacturer of using COVID-19 to ‘price-gouge’ British taxpayers The chief executive of NHS England has accused the manufacturer of a first-line medication for bipolar disorder of “trying to jack the prices of a long-standing medicine”.…
Warwick Smith: ‘The pandemic has removed factors that allowed us to be resilient for Brexit’ The director general of the British Generic Manufacturers Association speaks about how manufacturers are planning to juggle Brexit with COVID-19, and what the government can do to help.…
Health bodies make ‘urgent’ call to Matt Hancock to intervene in the proposed withdrawal of bipolar drug The health secretary, Matt Hancock, has been urged to “personally intervene” so that bipolar drug Priadel remains available in the UK with an appropriate pricing structure.…
Government in talks to offer drugs manufacturers incentives to diversify supply chains The British Generic Manufacturers Association is in talks with the government over incentivising drugs firms to obtain active pharmaceutical ingredients from more than one source to avoid future supply problems.…
First-line treatment for bipolar disorder Priadel to be discontinued in UK from April 2021 The manufacturer of first-line bipolar disorder treatment Priadel is discontinuing production of the medicine, the Medicines and Healthcare products Regulatory Agency has announced…
Government asks medicines manufacturers to stockpile drugs for end of Brexit transition period The government has asked drug manufacturers to rebuild six-week stockpiles of medicines in time for the UK’s transition period for leaving the EU ending on 31 December 2020.…
